ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2021
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- The evidence-based role of catecholaminergic PET tracers in Neuroblastoma. A systematic review and a head-to-head comparison with mIBG scintigraphy.European journal of nuclear medicine and molecular imaging · 2024Pooled it
- [European journal of nuclear medicine and molecular imaging · 2023Trial
- Radioligand therapy for pediatric patients with solid tumors.The British journal of radiology · 2026Review
- International neuroblastoma risk group consortium: a model of networking for rare cancers.Journal of the National Cancer Institute · 2026Article
- Simplified dosimetry using two-time-point kinetic modeling ofMedical physics · 2026Article
- hNET-targeted [Theranostics · 2026Article
- From Seeing to Healing: The Clinical Potential of Radiotracers in Pediatric Neuro-Oncology.Cancers · 2025Review
- Emerging Trends in Neuroblastoma Diagnosis, Therapeutics, and Research.Molecular neurobiology · 2025Review
- Unusual Bone Metastasis Neuroblastoma in Adolescent With Unidentified Primary Site.Clinical case reports · 2025Article
- Application of modified Curie and SIOPEN skeleton scoring systems inAnnals of nuclear medicine · 2025Article
- [Frontiers in oncology · 2025Article
- Biodistribution and radiation dosimetry ofEJNMMI physics · 2024Article
- Navigating new horizons: Prospects of NET-targeted radiopharmaceuticals in precision medicine.Theranostics · 2024Review
- Imaging of pediatric neuroblastoma: A COG Diagnostic Imaging Committee/SPR Oncology Committee White Paper.Pediatric blood & cancer · 2023Article
- Production Review of Accelerator-Based Medical Isotopes.Molecules (Basel, Switzerland) · 2022Review
- Advancing therapy for neuroblastoma.Nature reviews. Clinical oncology · 2022Review
- PET/MRI in Pediatric Neuroimaging: Primer for Clinical Practice.AJNR. American journal of neuroradiology · 2022Review
- Diagnostic Performance ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- [Radiological imaging of neuroblastoma].Der Radiologe · 2021Review
- Nuclear Medicine Imaging in Neuroblastoma: Current Status and New Developments.Journal of personalized medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
The metaiodobenzylguanidine (MIBG) scan is one of the most sensitive noninvasive lesion detection modalities for neuroblastoma. Unlike
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.